EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyseOpen Access · CC BY 4.0

Safety and Efficacy of Rechallenge With Immune Checkpoint Inhibitors in Advanced Solid Tumor: A Systematic Review and Meta‐Analysis

Huijun Xu, Yang Yang, Ying Yan, Mengge Li, Shusheng Wu, Lulu Cao, Wenju Chen, Huiqin Luo, Yifu He iD

Cancer Medicine · 2024-10 · 13 (20)

DOI: 10.1002/cam4.70324 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Cancer Medicine, online erschienen am 28.10.2024. Verfasst von Huijun Xu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Life Sciences and Medicine, Department of Oncology, the First Affiliated Hospital of USTC, University of Science and Technology of China,…. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Neoplasms. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Health Commission of Anhui Province Scientific Research Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Immune checkpoint inhibitors (ICIs) have drastically shifted the current landscape toward a wide variety of malignancies. However, ICIs are interrupted owing immune‐related adverse events (irAEs), therapy completion, and disease progression. The risk–benefit of rechallenged ICIs remains inconclusive. Herein, a systematic review and meta‐analysis were conducted to evaluate the safety and efficacy of ICI rechallenge in the treatment of advanced solid tumor.

Methods

PubMed, Web of Science, Embase, and Cochrane Library were searched to analyze the efficacy and safety of ICI rechallenge. The study protocol was approved by the PROSPERO International Register of Systematic Reviews (CRD42022372222). The last updated search date was March 2, 2024. Objective response rate (ORR), disease control rate (DCR), overall survival (OS), and incidence rates of all‐ and high‐grade irAEs were evaluated.

Results

A total of 41 retrospective studies comprising 2343 patients were ultimately enrolled for qualitative and quantitative assessments. A total of 1200 (51.2%) individuals were male and the median age was 66 years (range 18–97 years). The majority of the tumors was lung cancer ( n = 898, 38.3%). The occurrence rates of all‐grade and high‐grade (grade 3 or 4) irAEs between initial and readministration ICIs were not significantly different (all‐grade: OR, 0.75, 95% CI: 0.39–1.45, p = 0.40; I 2 = 87%; high‐grade: OR, 0.96, 95% CI: 0.62–1.49, p = 0.87, I 2 = 65%). ICIs restart presented a decreased ORR and DCR compared to initial ICI administration (ORR: OR, 0.36, 95% CI: 0.23–0.56, p < 0.00001; I 2 = 67%; DCR: OR, 0.62, 95% CI: 0.43–0.89, p = 0.010; I 2 = 53%). Seven studies with 513 patients for survival analysis revealed a nonsignificant difference in OS between the ICIs rechallenge and discontinuation cohorts (hazard ratio [HR]: 0.68, 95% confidence interval (CI): 0.35 to 1.35, p = 0.27).

Conclusion

Rechallenging immunotherapy is feasible, and patients should be carefully evaluated by a multidisciplinary team prior to initial therapy for close monitoring and assessment of the risk–benefit ratio. Therefore, prospective trials are essential to guide clinicians in the decision‐making process. PROSPERO Registration: CRD42022372222.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immune Checkpoint InhibitorsNeoplasmsHumansAgedMaleMiddle AgedFemaleAged, 80 and overTreatment OutcomeAdultYoung AdultAdolescent

Stichwörter der Autor:innen

immune checkpoint inhibitorsimmune‐related adverse eventsrechallengesolid tumor

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Division of Life Sciences and Medicine, Department of Oncology, the First Affiliated Hospital of USTC, University of Science and Technology of China, Hefei, Anhui, China.
  • Division of Life Sciences and Medicine, Department of Ultrasound, the First Affiliated Hospital of USTC, University of Science and Technology of China, Hefei, Anhui, China.

ORCID-Profile: Yifu He

Förderung

  • Health Commission of Anhui Province Scientific Research Project

Zitieren

APA

Xu, H., Yang, Y., Yan, Y., Li, M., Wu, S., Cao, L., Chen, W., Luo, H., & He, Y. (2024). Safety and Efficacy of Rechallenge With Immune Checkpoint Inhibitors in Advanced Solid Tumor: A Systematic Review and Meta‐Analysis. Cancer Medicine, 13(20). https://doi.org/10.1002/cam4.70324

Vancouver

Xu H, Yang Y, Yan Y, Li M, Wu S, Cao L, et al. Safety and Efficacy of Rechallenge With Immune Checkpoint Inhibitors in Advanced Solid Tumor: A Systematic Review and Meta‐Analysis. Cancer Medicine. 2024;13(20). doi:10.1002/cam4.70324

BibTeX
@article{Xu2024,
  author = {Xu, Huijun and Yang, Yang and Yan, Ying and Li, Mengge and Wu, Shusheng and Cao, Lulu and Chen, Wenju and Luo, Huiqin and He, Yifu},
  title = {Safety and Efficacy of Rechallenge With Immune Checkpoint Inhibitors in Advanced Solid Tumor: A Systematic Review and Meta‐Analysis},
  journal = {Cancer Medicine},
  year = {2024},
  volume = {13},
  number = {20},
  doi = {10.1002/cam4.70324}
}
Kostenlos starten →